CX11

DRUG4 trials

Sponsors

Corxel Pharmaceuticals Inc., Corxel Pharmaceuticals

Conditions

ObesityObesity & OverweightType 2 Diabetes MellitusType II Diabetes Mellitus

Phase 1

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

RecruitingNCT07652047

Corxel PharmaceuticalsObesity & Overweight

Start: 2026-05-11End: 2027-06-01Target: 90Updated: 2026-06-17

Phase 2

A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants

CompletedNCT07011797

Corxel PharmaceuticalsObesity

Start: 2025-06-17End: 2026-04-09Updated: 2026-05-28

A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus

RecruitingNCT07340320

Corxel PharmaceuticalsType II Diabetes Mellitus

Start: 2026-02-06End: 2027-04-30Target: 240Updated: 2026-09-15

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus.

Not yet recruitingCTIS2025-524514-28-00

Corxel Pharmaceuticals Inc.Type 2 Diabetes Mellitus

Target: 121Updated: 2026-04-22